Compare NUR & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUR | BOLT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 7.7M |
| IPO Year | 2016 | 2021 |
| Metric | NUR | BOLT |
|---|---|---|
| Price | $0.40 | $6.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 446.6K | ★ 692.8K |
| Earning Date | 08-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.36 | $5.89 |
| 52 Week High | $7.72 | $14.40 |
| Indicator | NUR | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 25.39 | 39.42 |
| Support Level | $0.36 | N/A |
| Resistance Level | $0.83 | $8.72 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 8.97 | 22.94 |
Nuran Wireless Inc is engaged in the Network as a Service (NAAS) business. The group operates in the research, development, manufacturing, marketing, and operation of digital electronic circuits and wireless telecommunication products and offers services in the mobile telephony industry. It also provides products and services that help mobile network operators profitably serve off-grid markets that are currently not served. It has two reportable segments: NaaS and Direct Sales. The majority of the revenue is derived from Africa.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.